These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32630450)

  • 1. Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C.
    Takemura K; Takizawa E; Tamori A; Nakamae M; Kubota H; Uchida-Kobayashi S; Enomoto M; Kawada N; Hino M
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
    Nagata H; Nakagawa M; Nishimura-Sakurai Y; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Goto F; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Tojo N; Tohda S; Asahina Y; Watanabe M;
    Hepatol Int; 2016 Nov; 10(6):956-964. PubMed ID: 27435935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C.
    Takemura K; Takizawa E; Tamori A; Nakamae M; Kubota H; Uchida-Kobayashi S; Enomoto M; Kawada N; Hino M
    J Gastroenterol Hepatol; 2021 Jan; 36(1):217-224. PubMed ID: 32453907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response.
    Sasaki R; Yamasaki K; Abiru S; Komori A; Nagaoka S; Saeki A; Hashimoto S; Bekki S; Kugiyama Y; Kuno A; Korenaga M; Togayachi A; Ocho M; Mizokami M; Narimatsu H; Ichikawa T; Nakao K; Yatsuhashi H
    PLoS One; 2015; 10(6):e0129053. PubMed ID: 26070204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
    Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
    J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection.
    Toyoda H; Yasuda S; Shiota S; Sone Y; Maeda A; Kaneoka Y; Kumada T; Tanaka J
    Eur Radiol; 2022 Jul; 32(7):5016-5023. PubMed ID: 35142900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C.
    Yamazaki T; Joshita S; Umemura T; Usami Y; Sugiura A; Fujimori N; Shibata S; Ichikawa Y; Komatsu M; Matsumoto A; Igarashi K; Tanaka E
    Sci Rep; 2017 Apr; 7():46705. PubMed ID: 28425454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein.
    Sato S; Genda T; Ichida T; Amano N; Sato S; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Hirano K; Shimada Y; Iijima K; Wada R; Nagahara A; Watanabe S
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs.
    Nakagawa M; Nawa N; Takeichi E; Shimizu T; Tsuchiya J; Sato A; Miyoshi M; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Fujiwara T; Watanabe M; Tanaka Y; Asahina Y;
    J Gastroenterol; 2020 Oct; 55(10):990-999. PubMed ID: 32770465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    Nagata H; Nakagawa M; Asahina Y; Sato A; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Nouchi T; Sakai H; Tomita M; Watanabe M;
    J Hepatol; 2017 Nov; 67(5):933-939. PubMed ID: 28627363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
    Yamazaki T; Joshita S; Umemura T; Usami Y; Sugiura A; Fujimori N; Kimura T; Matsumoto A; Igarashi K; Ota M; Tanaka E
    PLoS One; 2018; 13(4):e0195632. PubMed ID: 29617443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response.
    Chida T; Ohta K; Noritake H; Matsushita M; Murohisa G; Kageyama F; Sasada Y; Oyaizu T; Tsugiki M; Tamakoshi K; Nakajima T; Suda T; Kawata K
    Sci Rep; 2024 May; 14(1):10864. PubMed ID: 38740815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma.
    Fujiyoshi M; Kuno A; Gotoh M; Fukai M; Yokoo H; Kamachi H; Kamiyama T; Korenaga M; Mizokami M; Narimatsu H; Taketomi A;
    J Gastroenterol; 2015 Nov; 50(11):1134-44. PubMed ID: 25773774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor.
    Osawa L; Tamaki N; Kurosaki M; Kirino S; Watakabe K; Wang W; Okada M; Shimizu T; Higuchi M; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis.
    Su TH; Peng CY; Tseng TC; Yang HC; Liu CJ; Liu CH; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2020 Feb; 221(4):589-597. PubMed ID: 31574141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.
    Akuta N; Suzuki F; Sezaki H; Kobayashi M; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30381417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
    J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy.
    Murata A; Amano N; Sato S; Tsuzura H; Tomishima K; Sato S; Matsumoto K; Shimada Y; Iijima K; Genda T
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients.
    Kikukawa K; Uchida-Kobayashi S; Tamori A; Yoshida K; Kotani K; Motoyama H; Kozuka R; Hagihara A; Fujii H; Morikawa H; Enomoto M; Murakami Y; Kawada N
    Ann Hepatol; 2020; 19(4):367-372. PubMed ID: 32444247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C.
    Ura K; Furusyo N; Ogawa E; Hayashi T; Mukae H; Shimizu M; Toyoda K; Murata M; Hayashi J
    Aliment Pharmacol Ther; 2016 Jan; 43(1):114-24. PubMed ID: 26503582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.